SCHEMBL24252913

SCHEMBL24252913

COCCOCCOc1ccc(Cl)cc1Br

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.61
KDM4E B2RXH2 6/20 0.61
ALDH1A1 P00352 6/20 0.61
GAA P10253 2/20 0.59
MAPT P10636 4/20 0.58
LMNA P02545 3/20 0.58
HTT P42858 2/20 0.58
HPGD P15428 1/20 0.58
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
TDP1 Q9NUW8 3/20 0.54
L3MBTL1 Q9Y468 3/20 0.51
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
S1PR4 O95977 1/20 0.50
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25244529 1.00 SMN1; SMN2 (0.61) SMN1; SMN2KDM4EALDH1A1GAAMAPT
SCHEMBL30451378 1.00 SMN1; SMN2 (0.61) SMN1; SMN2KDM4EALDH1A1GAAMAPT
SCHEMBL29684781 0.95 KDM4E (0.60) SMN1; SMN2KDM4EALDH1A1GAAMAPT
SCHEMBL8399454 0.89 KDM4E (0.52) SMN1; SMN2KDM4EALDH1A1GAAMAPT
SCHEMBL16555251 0.81 SLC6A4 (0.49) SMN1; SMN2KDM4EALDH1A1GAAMAPT
SCHEMBL30148118 0.81 L3MBTL1 (0.51) SMN1; SMN2KDM4EALDH1A1GAAMAPT
SCHEMBL14870995 0.81 L3MBTL1 (0.51) SMN1; SMN2KDM4EALDH1A1GAAMAPT
SCHEMBL22498464 0.81 ALDH1A1 (0.52) SMN1; SMN2KDM4EALDH1A1GAAMAPT
SCHEMBL1371009 0.80 KDM4E (0.51) SMN1; SMN2KDM4EALDH1A1GAAMAPT
SCHEMBL14345658 0.79 HTR2C (0.52) KDM4EALDH1A1MAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 SMN1; SMN2 782/4885KDM4E 3923/4885ALDH1A1 653/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 SMN1; SMN2 782/4885KDM4E 3923/4885ALDH1A1 653/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 SMN1; SMN2 782/4885KDM4E 3923/4885ALDH1A1 653/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH SMN1; SMN2 237/4885KDM4E 2913/4885ALDH1A1 3178/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 SMN1; SMN2 1451/4885KDM4E 4178/4885ALDH1A1 3094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.